Pediatric Oncology

Socioeconomic status had no impact on complete remission rates or overall survival among younger patients who received chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia, study results showed.

Dual administration of CD19- and CD22-directed chimeric antigen receptor T cells conferred a 99% complete remission rate in younger patients with relapsed or high-risk B-cell acute lymphoblastic leukemia, phase 2 study results showed.

Next-generation sequencing and precision medicine techniques have enabled the identification of millions of somatic cancer variants.

The oncolytic adenovirus DNX-2401 appeared safe and feasible among a small cohort of pediatric patients with diffuse intrinsic pontine glioma, according to study results published in The New England Journal of Medicine.

Crystal L. Mackall, MD, believes she has an "unusual pedigree" for someone in her position.

Genomic sequencing of tumors enabled 107 patients with pediatric cancer who experienced relapse to receive an appropriate matched therapy that is not standard of care, according to study results reported in Cancer Discovery.

Emily E. Johnston, MD, MS, prides herself on being there for her pediatric oncology patients at every step of their cancer journeys.

Onkos Surgical Inc. has announced a definitive agreement with Stryker for the acquisition of the Juvenile Tumour System, an extendible prosthesis system for pediatric patients with bone cancer, according to an Onkos Surgical press release.

A phase 2/phase 3 study assessed intramuscular asparaginase Erwinia chrysanthemi (recombinant)-rywn for patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who developed hypersensitivity to E. coli-derived L-asparaginase.

CHICAGO — Combining brentuximab vedotin with a chemotherapy regimen as first-line therapy conferred an objective response in 88% of younger patients with newly diagnosed advanced-stage classical Hodgkin lymphoma, study results show.